Sunshine Nora: In the first instance judgment, Hengsheng Pharmaceuticals should pay 2.4032 million yuan.

Yangguang Nuohe announced that in the first-instance judgment of the lawsuit where the company acted as a defendant and counterclaimant, Hengsheng Pharmaceuticals paid the company 4.4032 million yuan in research and development expenses and compensation. The company compensated Hengsheng Pharmaceuticals with 2 million yuan, and after offsetting, Hengsheng Pharmaceuticals still needed to pay 2.4032 million yuan. The total litigation fees for this lawsuit and counterclaim amounted to 122,500 yuan, with Hengsheng Pharmaceuticals responsible for 74,500 yuan and the company responsible for 48,000 yuan. Since the company has fully provisioned for the relevant accounts receivable as bad debts, this lawsuit will not have a negative impact on the current and future profits. The case is currently in the appellate period, and the final impact will depend on the actual execution of the judgment.